Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXCALIBER-RRMM
2020-000431-49Phase 3Active
- Sponsor
- Celgene Corporation
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of iberdomide, daratumumab, bortezomib and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free survival. Started Apr 2021; status: active.
02
Drugs
iberdomidedaratumumabbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2020-000431-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000431-49.